Pasithea Therapeutics Corp. (NASDAQ:KTTA) announced Thursday that its board of directors has set September 3, 2025, as the date for the company's 2025 annual meeting of stockholders. According to a statement in a press release filed with the Securities and Exchange Commission, the company expects to begin delivering and making available proxy materials for the meeting on or about July 24.
The company noted that the 2025 annual meeting will occur more than 30 days after the anniversary of its 2024 annual meeting. As a result, Pasithea Therapeutics is providing deadlines for stockholders interested in submitting proposals or director nominations for consideration at the meeting.
Stockholders who wish to present proposals for inclusion in the proxy materials under SEC Rule 14a-8 must submit them in writing to the company's principal executive offices at 1111 Lincoln Road, Suite 500, Miami Beach, FL 33139, no later than July 21, 2025. The company stated that this deadline is a reasonable time before it expects to begin distributing its proxy materials and that all proposals must comply with applicable requirements under Rule 14a-8.
In addition, stockholders intending to solicit proxies in support of director nominees other than the company's nominees must provide notice with the information required by Rule 14a-19 of the Securities Exchange Act by July 21, 2025. This deadline is the tenth calendar day following the public announcement of the meeting date.
Pasithea Therapeutics' common stock and warrants are listed on the Nasdaq Capital Market under the symbols KTTA and KTTAW, respectively.
All information is based on a press release statement included in the company's Form 8-K filing with the SEC.
In other recent news, Pasithea Therapeutics Corp. has reported interim results from a Phase 1 trial of its drug PAS-004, demonstrating promising clinical activity in treating refractory solid tumors. The trial, which included 21 patients with advanced tumors, showed stable disease in 10 out of 16 efficacy-evaluable patients, with progression-free survival reaching up to 159 days. The company's CEO, Dr. Tiago Reis Marques, highlighted the drug's potential as a MEK inhibitor with high selectivity and prolonged target engagement. Additionally, Pasithea released preclinical findings suggesting PAS-004 could effectively inhibit inflammatory responses linked to inflammatory bowel disease, outperforming the FDA-approved MEK inhibitor selumetinib. The research conducted at the Francis Crick Institute indicated that PAS-004 downregulated ETS2-regulated genes and reduced macrophage functions crucial to chronic inflammation. Dr. Marques expressed optimism about PAS-004's potential as a new oral treatment for inflammatory diseases. The company is also conducting a Phase 1/1b trial of PAS-004 for neurofibromatosis type 1-associated plexiform neurofibromas. Pasithea continues to focus on developing treatments for CNS disorders and MAPK pathway-driven tumors.